GlassScriptPhysician profile
Kasra Maasumi
NPI 1306161963
$388,051.81
in general payments reported to CMS, 2019-2025
24 companies · $10K in 2025
The $10K reported for 2025 was more than what 94% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $46K · 2021: $188K · 2022: $53K · 2023: $31K · 2024: $13K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $6,309 · Food and Beverage: $3,491 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,575.00 |
| Travel and Lodging | $6,308.60 |
| Food and Beverage | $3,490.78 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $122,952.07 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $115,212.23 | 2020-2021 | |
| Allergan, INC. | $58,134.27 | 2019-2022 | |
| Amgen INC. | $33,846.84 | 2019-2023 | Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $29,785.88 | 2022 | |
| Lilly USA, LLC | $11,161.35 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $10,519.60 | 2019-2024 | Ajovy |
| Spinal Simplicity, LLC | $2,004.06 | 2021-2022 | |
| Medtronic, INC. | $1,448.73 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Medtronic USA, INC. | $1,222.49 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $538.77 | 2022-2023 | Trudhesa |
| Boston Scientific Corporation | $343.57 | 2020-2023 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $293.68 | 2019-2024 | Proclaim |
| Curonix LLC | $166.06 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Averitas Pharma INC. | $118.80 | 2024 | Qutenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $73.88 | 2023 | Dynacord |
| Stimwave Technologies Incorporated | $68.47 | 2021-2022 | |
| Nalu Medical, INC. | $49.61 | 2024 | Nalu Neurostimulation System |
| Pfizer INC. | $30.71 | 2023 | |
| Painteq LLC | $19.21 | 2023 | Painteq |
| Axonics, INC. | $16.30 | 2021 | |
| Relievant Medsystems, INC. | $16.27 | 2022 | |
| Biodelivery Sciences International, INC. | $14.51 | 2021 | |
| Scilex Pharmaceuticals INC. | $14.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasra Maasumi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.